Market Alert: Manitex International,, Cesca Therapeutics Inc. (NASDAQ:KOOL), EV Energy Partners LP (NASDAQ:EVEP), Cempra (NASDAQ:CEMP), Endocyte (NASDAQ:ECYT)


Manitex International, Inc. (NASDAQ:MNTX) shares decreased -2.06% in last trading session and ended the day at $6.64. MNTX Gross Margin is 18.00% and its has a return on assets of -1.30%. Manitex International, Inc. (NASDAQ:MNTX) quarterly performance is 35.23%.

Cesca Therapeutics Inc. (NASDAQ:KOOL) ended the last trading day at $3.08. Company weekly volatility is calculated as 5.33% and price to cash ratio as 3.26. Cesca Therapeutics Inc. (NASDAQ:KOOL) showed a weekly performance of -9.14%.

Cesca Therapeutics Inc. (NASDAQ:KOOL), presented a poster titled “Volume Reduction and RBC Depletion of Apheresis Products for Transplant” at the 42nd Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT) held in Valencia, Spain on April 3 – 6, 2016.

On 22 April, EV Energy Partners LP (NASDAQ:EVEP) shares moved up 11.42% and was closed at $2.83. EVEP EPS growth in last 5 year was -28.10%. EV Energy Partners LP (NASDAQ:EVEP) year to date (YTD) performance is 3.73%.

EV Energy Partners, L.P. (NASDAQ:EVEP) announced the company presented at the Independent Petroleum Association of American (IPAA) Oil and Gas Investment Symposium (OGIS) in New York on Monday, April 11, 2016 at 9:10 a.m. Eastern Time.

Cempra, Inc. (NASDAQ:CEMP) shares moved up 0.68% in last trading session and ended the day at $19.20. CEMP has a return on assets of -46.50%. Cempra, Inc. (NASDAQ:CEMP) quarterly performance is -2.64%.

Cempra, Inc. (NASDAQ:CEMP), announced it participated in the 15th Annual Needham and Company Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, presented at 1:40 p.m. ET on Wednesday, April 13, 2016 in New York City.

Endocyte, Inc. (NASDAQ:ECYT) caters to the Healthcare space. Its weekly performance is 4.04%. On the last day of trading company shares ended up at $4.12.

On 19 April, Endocyte, Inc. (NASDAQ:ECYT), announced in a late-breaking poster session the presentation of new research from investigators and faculty at the Purdue University Center for Drug Discovery on the application of Endocyte’s SMDC technology in a chimeric antigen receptor (CAR) therapy setting (Poster #LB-254 – A Universal Remedy for CAR T cell limitations) at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.


Leave a Reply

Your email address will not be published. Required fields are marked *